Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
HCC1806
TNBC
Basal A
Nutlin 3a
MDM2
MDM2
7451.066
uM
30.75380
40.36790
-0.4347 -0.7136 3.2597 0.1026
0.9964
2.0040
HCC1806
TNBC
Basal A
Olomoucine II
CDK1
CDK
12239.147
uM
8.33890
11.24390
-0.6158 -0.6191 2.6956 0.3167
0.9978
2.0027
HCC1806
TNBC
Basal A
Omipalisib
PI3K
PI3K
7451.086
uM
0.04011
0.13686
-0.5411 -0.5438 0.5997 0.6623
0.9944
1.9434
HCC1806
TNBC
Basal A
Oxaliplatin
DNA cross-linker
DNA cross-linker
9376.011
uM
4.45210
17.95240
-0.8709 -1.0000 0.7879 0.5509
0.9784
1.5809
HCC1806
TNBC
Basal A
Oxaliplatin
DNA cross-linker
DNA cross-linker
7829.011
uM
2.20680
12.14170
-0.8339 -1.0000 0.6443 0.6323
0.9812
1.8746
HCC1806
TNBC
Basal A
Oxamflatin
HDAC
HDAC
12239.147
uM
0.96507
2.60940
-0.8254 -0.9653 1.0809 0.5157
0.9885
2.0027
HCC1806
TNBC
Basal A
PD 98059
MEK
MAPK
12239.152
uM
inf
inf
0.9055 0.9055 0.0000 0.0656
-0.0219
2.2104
HCC1806
TNBC
Basal A
PD173074
FGFR1/3
RTK
7451.093
uM
4.57730
6.63020
-0.4720 -0.5343 1.9616 0.2371
0.9894
2.1935
HCC1806
TNBC
Basal A
PD184352
MEK
MAPK
12239.155
uM
inf
inf
0.9084 0.9084 0.0000 0.0478
0.4412
2.1474
HCC1806
TNBC
Basal A
PD184352
MEK
MAPK
12239.155
uM
inf
inf
0.9084 0.9084 0.0000 0.0478
0.4412
2.1474
HCC1806
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7451.095
uM
inf
inf
0.7452 0.7452 0.0000 0.2906
0.3518
2.2028
HCC1806
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7450.095
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
1.7844
HCC1806
TNBC
Basal A
PS-1145
IKK
NFKB
7450.065
uM
inf
inf
1.0181 1.0181 0.0000 0.0205
0.0000
2.4231
HCC1806
TNBC
Basal A
PS-1145
IKK
NFKB
7451.065
uM
inf
180.29960
0.9525 0.9339 0.2460 0.0196
0.6361
2.1525
HCC1806
TNBC
Basal A
Purvalanol A
CDK1
CDK
7451.067
uM
inf
inf
0.8609 0.8609 0.0000 0.0355
0.3320
2.0570
HCC1806
TNBC
Basal A
Purvalanol A
CDK1
CDK
7450.067
uM
34.25460
25.24120
0.3917 0.3914 5.0000 0.0798
0.9827
2.2419
HCC1806
TNBC
Basal A
QNZ
NFkB
NFKB
7451.096
uM
inf
0.06767
0.6556 0.6764 1.5258 0.1610
0.9845
2.1851
HCC1806
TNBC
Basal A
SB-3CT
MMP2/9
MMP
12239.144
uM
inf
142.19340
0.8314 0.6181 0.6735 0.0345
0.8344
2.1598
HCC1806
TNBC
Basal A
Selumetinib
MEK
MAPK
12239.155
uM
inf
0.33687
0.7885 0.7813 0.9393 0.0895
0.8826
2.1474
HCC1806
TNBC
Basal A
Sigma A6730
AKT
AKT
12239.165
uM
9.67380
17.26610
-0.8465 -0.9909 1.8858 0.2211
0.9992
2.0705
HCC1806
TNBC
Basal A
Sirolimus
MTOR
MTOR
7830.068
uM
inf
inf
0.6889 0.6889 0.0000 0.1423
0.5692
1.8365
HCC1806
TNBC
Basal A
Sirolimus
MTOR
MTOR
7450.069
uM
inf
0.61592
0.8392 0.8488 1.1485 0.0327
0.8505
2.2471
HCC1806
TNBC
Basal A
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7450.084
uM
inf
inf
0.5029 0.5029 0.0000 0.0525
0.3472
2.3432
HCC1806
TNBC
Basal A
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7451.085
uM
54.5510
77.17010
-0.8510 -0.8768 2.9202 0.2342
0.9942
2.1458
HCC1806
TNBC
Basal A
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7450.067
uM
8.65720
13.48560
-0.9123 -0.9159 2.3484 0.3507
0.9981
2.2419